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INTRODUCTION 
The Bioaccessibility Research Group of Europe is a European network bringing together 
international institutes to study human bioaccessibility of priority contaminants in soils such 
as arsenic (As), lead (Pb) and cadmium (Cd) via the gastrointestinal (GI) tract.  A primary 
objective is to provide robust and defensible bioaccessibility data that can be used in human 
health risk assessments and policy making. The correct estimation of bioaccessibility has the 
potential to make a significant impact on current risk assessment practices. To this end 
BARGE has been involved in comparing and evaluating physico-chemical processes within 
the many models that have been developed to measure bioaccessibility and contaminant 
exposure (Wragg et al., 2011).  Because variable results from method comparison studies 
(Oomen et al., 2002) have hindered the adoption of bioaccessibility methods by some in the 
regulatory community, BARGE initiated the development of a harmonised in vitro 
bioaccessibility test: the Unified BARGE Method (UBM). 
 
METHODS 
The chosen method was based on a previously published method developed by researchers 
at the Dutch Institute of Public Health, the RIVM (Oomen et al., 2002).  This physiologically-
based method had gained a degree of regulatory acceptance in both the Netherlands and 
Denmark, and was considered more likely to be adopted by testing laboratories.  The RIVM 
method was optimised to provide conservative and robust estimates, and to be applicable to 
various soils of different parent geologies.  
 
Inter-laboratory trial of the UBM 
An International inter-laboratory trial was set-up to determine the repeatability and 
reproducibility of results within and between testing laboratories (Wragg et al., 2011).  The 
target within and between laboratory reproducibility and repeatability criteria were set at 10% 
and 20% RSD respectively.  Seven laboratories participated, extracting 34 contaminated 
samples (soils, mine wastes and slag materials).  One central laboratory handled all sample 
transit, analysis, data analysis and data reporting for the trial. 
 
In-vivo validation of the UBM 
In parallel to the inter-laboratory trial, INERIS and the University of Nancy undertook the 
validation of the UBM for As, Cd and Pb using a juvenile swine model.  The in vivo end 
points were liver, bone, kidney and urine and in total 15 soils were tested. 
 
RESULTS AND DISCUSSION 
 
Inter-laboratory trial 
The trial showed it was difficult to meet the between laboratory repeatability criteria (20% 
RSD), which was thought to be a result of minor differences in laboratory techniques despite 
a standardised method being supplied to all participants.  The UBM met the stated 
benchmark criteria for in vivo validation (a vivo/vitro linear relationship, a very strong 
correlation coefficient (r >0.8 or r2 >0.6) and a slope >0.8 and < 1.2) for both the GI phases 
for As and the stomach phase for Cd.  For the ‘stomach & intestine’ phase Cd and Pb r and 
r2 values of 0.51 – 0.76 were returned with slopes of 0.44 – 0.57.  
 
In-vivo validation of the UBM 
Caboche (2009) showed that correlation between the relative bioavailability and 
bioaccessibility of As, Pb and Cd was highly significant, both for the gastric and the gastro-
intestinal phases (p<0.01).  r2 values of >0.97 and >0.89 were obtained for vivo/vitro 
correlations for As in urine and Cd/Pb in the kidney respectively.  The slopes of the 
regressions were all > 0.9 and <1.1 and the intercepts were not significantly different from 0. 
Example in vivo/in vitro correlation plots plots for Pb are shown in Figure 1. 
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Fig. 1 in vivo/in vitro correlation plots for Pb in the stomach and intestine compartments (dot 
dash is the line of equivalence, solid is the median regression line and dotted lines are 
the 95% confidence limits 
 
CONCLUSIONS 
A significant amount of work has been carried out by BARGE in order to optimise one 
method and produce a robust, validated in vitro model for use in human health risk 
assessment.  To date, the in vivo validation has showed that setting of the ‘stomach’ pH to 
1.2±.05 rather than 1.2-1.4, as used in the inter-laboratory trial, may reduce the between 
laboratory variability to <20% RSD.  A follow up trial with a refined laboratory procedure is 
planned. The UBM is now being used routinely in Europe on a variety of applications to aid in 
the assessment human health risk from contaminated soils.   
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